Last updated on October 2017

BAX 802 in CHA With Inhibitors


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.

Clinical Study Identifier: NCT02895945

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Michael Krammer, MSc

Bleeding and Clotting Disorders Institute
Peoria, IL United States
  Connect »

Michael Krammer, MSc

Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l' le-de-Montr al
Montréal, QC Canada
  Connect »

Michael Krammer, MSc

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-1-AMF7BT
Milano, Italy
  Connect »

Michael Krammer, MSc

UMC Utrecht-1-1YA-3214
Utrecht, Netherlands
  Connect »

Michael Krammer, MSc

Instytut Hematologii i Transfuzjologii-1-1Y7-1347
Warszawa, Poland
  Connect »

Michael Krammer, MSc

Hospital Universitari i Politecnic La Fe
Valencia, Spain
  Connect »

Michael Krammer, MSc

Complejo Hospitalario Universitario A Coru a-1-2WKDXY
La Coruña, Spain
  Connect »

Michael Krammer, MSc

Hospital Universitario La Paz-1-IKVQAW
Madrid, Spain
  Connect »

Michael Krammer, MSc

Royal Free Hospital
London, United Kingdom
  Connect »

Michael Krammer, MSc

St Thomas' Hospital-1-M6DQZK
London, United Kingdom
  Connect »

Michael Krammer, MSc

Manchester Royal Infirmary-1-1PA3SZ
Manchester, United Kingdom
  Connect »